Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2016 May;14(5):509-19.
doi: 10.6004/jnccn.2016.0060.

NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016

Peter R Carroll  1 , J Kellogg Parsons  2 , Gerald Andriole  3 , Robert R Bahnson  4 , Erik P Castle  5 , William J Catalona  6 , Douglas M Dahl  7 , John W Davis  8 , Jonathan I Epstein  9 , Ruth B Etzioni  10 , Thomas Farrington  11 , George P Hemstreet 3rd  12 , Mark H Kawachi  13 , Simon Kim  14 , Paul H Lange  15 , Kevin R Loughlin  16 , William Lowrance  17 , Paul Maroni  18 , James Mohler  19 , Todd M Morgan  20 , Kelvin A Moses  21 , Robert B Nadler  6 , Michael Poch  22 , Chuck Scales  23 , Terrence M Shaneyfelt  24 , Marc C Smaldone  25 , Geoffrey Sonn  26 , Preston Sprenkle  27 , Andrew J Vickers  28 , Robert Wake  29 , Dorothy A Shead  30 , Deborah A Freedman-Cass  30
Affiliations
Practice Guideline

NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016

Peter R Carroll et al. J Natl Compr Canc Netw. 2016 May.

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer Early Detection provide recommendations for prostate cancer screening in healthy men who have elected to participate in an early detection program. The NCCN Guidelines focus on minimizing unnecessary procedures and limiting the detection of indolent disease. These NCCN Guidelines Insights summarize the NCCN Prostate Cancer Early Detection Panel's most significant discussions for the 2016 guideline update, which included issues surrounding screening in high-risk populations (ie, African Americans, BRCA1/2 mutation carriers), approaches to refine patient selection for initial and repeat biopsies, and approaches to improve biopsy specificity.

PubMed Disclaimer

References

    1. Andriole GL. Update of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Recent Results Cancer Res 2014;202:53–57. - PubMed
    1. Andriole GL, Crawford ED, Grubb RL III, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012;104:125–132. - PMC - PubMed
    1. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320–1328. - PubMed
    1. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981–990. - PMC - PubMed
    1. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384:2027–2035. - PMC - PubMed

Publication types